世界のGLP-1アゴニスト減量薬の市場規模は、2024年に138億4000万ドルと推定され、2025年から2030年にかけて18.54%のCAGRで成長すると予測されます。GLP-1アゴニスト減量薬の市場は、肥満率の上昇、健康意識の高まり、セマグルチド(Wegovy、Ozempic) やチルゼパチド(Mounjaro、Zepbound) などの薬剤の強力な臨床効果により、急速な成長を遂げています。医薬品の進歩、規制当局の有利な承認、保険適用範囲の拡大が、採用をさらに加速させています。さらに、有名人の推薦やソーシャルメディアの影響により、消費者の需要が高まり、市場は糖尿病患者を超えてより広範な体重管理セグメントに拡大しています。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. GLP-1 Agonists Weight Loss Drugs Market Variables, Trends, & Scope
3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Rising prevalence of obesity
3.3.1.2. Increasing adoption of weight loss drug therapy
3.3.1.3. Rising geriatric population
3.3.2. Market Restraints Analysis
3.3.2.1. High cost of treatment
3.3.2.2. Stringent regulations pertaining to production and approvals
3.4. GLP-1 Agonists Weight Loss Drugs Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social Landscape
3.4.2.3. Technological Landscape
3.4.2.4. Environmental Landscape
3.4.2.5. Legal Landscape
Chapter 4. GLP-1 Agonists Weight Loss Drugs Market: By Drug Estimates & Trend Analysis
4.1. GLP-1 Agonists Weight Loss Drugs Market: Drug Segment Dashboard
4.2. GLP-1 Agonists Weight Loss Drugs Market: By Drug Movement Analysis, 2024 & 2030 (USD Million)
4.3. Semaglutide (Wegovy)
4.3.1. Semaglutide (Wegovy) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Liraglutide (Saxenda)
4.4.1. Liraglutide (Saxenda) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Tirzepatide (Zepbound)
4.5.1. Tirzepatide (Zepbound) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Other Drugs
4.6.1. Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Estimates & Trend Analysis
5.1. GLP-1 Agonists Weight Loss Drugs Market: Route of Administration Segment Dashboard
5.2. GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
5.3. Parenteral
5.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Oral
5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Estimates & Trend Analysis
6.1. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Segment Dashboard
6.2. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
6.3. Hospital Pharmacies
6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Other Pharmacies
6.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. GLP-1 Agonists Weight Loss Drugs Market: Regional Estimates & Trend Analysis
7.1. GLP-1 Agonists Weight Loss Drugs Market Share, By Region, 2024 & 2030 (USD Million)
7.2. North America
7.2.1. North America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018- 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Norway
7.3.8.1. Norway GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Sweden
7.3.9.1. Sweden GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. UAE
7.6.3.1. UAE GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. Kuwait
7.6.4.1. Kuwait GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. South Africa
7.6.5.1. South Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis, 2024
8.5. Company Profiles
8.5.1. Eli Lilly and Company.
8.5.1.1. Participant’s Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Recent Developments/ Strategic Initiatives
8.5.2. Pfizer Inc.
8.5.2.1. Participant’s Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Recent Developments/ Strategic Initiatives
8.5.3. Novo Nordisk A/S
8.5.3.1. Participant’s Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Recent Developments/ Strategic Initiatives
8.5.4. Viking Therapeutics
8.5.4.1. Participant’s Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Recent Developments/ Strategic Initiatives
8.5.5. Structure Therapeutics
8.5.5.1. Participant’s Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Recent Developments/ Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 4 Global GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 5 Global GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 6 North America GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
Table 7 North America GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 8 North America GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 9 North America GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 10 U.S. GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 11 U.S. GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 12 U.S. GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 13 Canada GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 14 Canada GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 15 Canada GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 16 Mexico GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 17 Mexico GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 18 Mexico GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Europe GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
Table 20 Europe GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 21 Europe GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 22 Europe GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 23 Germany GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 24 Germany GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 25 Germany GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 26 UK GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 27 UK GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 28 UK GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 29 France GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 30 France GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 31 France GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Italy GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 33 Italy GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 34 Italy GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 35 Spain GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 36 Spain GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 37 Spain GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 38 Denmark GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 39 Denmark GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 40 Denmark GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 41 Sweden GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 42 Sweden GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 43 Sweden GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 44 Norway GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 45 Norway GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 46 Norway GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
Table 48 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 49 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 50 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 51 China GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 52 China GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 53 China GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 54 Japan GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 55 Japan GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 56 Japan GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 57 India GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 58 India GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 59 India GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 60 South Korea GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 61 South Korea GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 62 South Korea GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 63 Australia GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 64 Australia GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 65 Australia GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 66 Thailand GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 67 Thailand GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 68 Thailand GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 69 Latin America GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
Table 70 Latin America GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 71 Latin America GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 72 Latin America GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 73 Brazil GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 74 Brazil GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 75 Brazil GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 76 Argentina GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 77 Argentina GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 78 Argentina GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 79 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 83 South Africa GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 84 South Africa GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 85 South Africa GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 89 UAE GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 90 UAE GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 91 UAE GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
Table 92 Kuwait GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
Table 93 Kuwait GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
Table 94 Kuwait GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & forecasting
Fig. 6 Market formulation & Validation
Fig. 7 GLP-1 Agonists Weight Loss Drugs, Market Segmentation
Fig. 8 Market Snapshot, 2024
Fig. 9 Market Trends & Outlook
Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five forces Analysis
Fig. 14 Global GLP-1 Agonists Weight Loss Drugs Market: By Drug Movement Analysis
Fig. 15 Global GLP-1 Agonists Weight Loss Drugs Market, for Semaglutide (Wegovy), 2018 - 2030 (USD Million)
Fig. 16 Global GLP-1 Agonists Weight Loss Drugs Market, for Liraglutide (Saxenda), 2018 - 2030 (USD Million)
Fig. 17 Global GLP-1 Agonists Weight Loss Drugs Market, for Tirzepatide (Zepbound), 2018 - 2030 (USD Million)
Fig. 18 Global GLP-1 Agonists Weight Loss Drugs Market, for Other Drugs, 2018 - 2030 (USD Million)
Fig. 19 Global GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Movement Analys
Fig. 20 Global GLP-1 Agonists Weight Loss Drugs Market, for Parenteral 2018 - 2030 (USD Million)
Fig. 21 Global GLP-1 Agonists Weight Loss Drugs Market, for Oral, 2018 - 2030 (USD Million)
Fig. 22 Global GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Movement Analysis
Fig. 23 Global GLP-1 Agonists Weight Loss Drugs Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
Fig. 24 Global GLP-1 Agonists Weight Loss Drugs Market, for Retail Pharmacies, 2018 - 2030 (USD Million)
Fig. 25 Global GLP-1 Agonists Weight Loss Drugs Market, for Other Pharmacies, 2018 - 2030 (USD Million)
Fig. 26 Regional Marketplace: Key Takeaways GLP-1 Agonists Weight Loss Drugs Market, Region 2018 -
Fig. 27 Regional Outlook, 2022 & 2030 GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 28 Global GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 29 North America GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 30 US GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 31 Canada GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 32 Mexico GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 33 Europe GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 34 Germany GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 35 UK GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 36 France GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 37 Italy GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 38 Spain GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 39 Denmark GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 40 Sweden GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 41 Norway GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 42 Asia Pacific GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 43 Japan GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 44 China GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 45 India GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 46 Australia GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 47 South Korea GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 48 Thailand GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 49 Latin America GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 50 Brazil GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 51 Argentina GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 52 Middle East and Africa GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 53 South Africa GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 54 Saudi Arabia GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 55 UAE GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 56 Kuwait GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
Fig. 57 Company/Competition Categorization
Fig. 58 Company Market Share Analysis, 2024
Fig. 59 Company Market Position Analysis, 2024
Fig. 60 Strategy Mapping
